M&A boost as Johnson & Johnson bids for Actelion
Johnson & Johnson has offered Actelion a 23% premium on its shares in a $30bn all-cash bid, in what would be the largest European pharmaceuticals transaction in a decade. And with M&A activity strong during January, investment grade loan bankers are feeling more optimistic.
After talks that began in December, Johnson & Johnson on Thursday offered Actelion shareholders $280 a share in the all-cash offer. If accepted, the US company will start the tender offer by mid-February.A bridge facility to back the buyout ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com